Strong equity market performance and resilient investor demand for growth-oriented issuers have sustained IPO activity through late 2026, with multiple U.S. and international offerings priced or scheduled for November and December. Biotech and healthcare names such as Rezera Inc. (targeting mid-November pricing) and Windward Bio Group AG, alongside filings from Anthropic and others, illustrate a pipeline that remains active despite selective delays for larger or more volatile candidates. Year-to-date proceeds already rank as the second-highest on record, reflecting favorable monetary policy conditions and sector-specific tailwinds in AI-adjacent and life sciences businesses. Key near-term catalysts include additional pricing dates through year-end and any final regulatory clearances that could accelerate or defer remaining deals into 2027.